EZH2 and acute myeloid leukemia: Similar group performed research on HASNPs encapsulated with an EZH2‐specific inhibitor, EPZ011989, that facilitates an efficient drug loading and sustainable release, thus increasing cellular uptake and nuclear localization of nanocomposite in human AML cell lines.